Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.
Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, Biella, Italy.
BMC Cancer. 2021 Jul 28;21(1):865. doi: 10.1186/s12885-021-08576-z.
Cholangiocarcinoma (CCA) is an aggressive disease with poor prognosis. A molecular classification based on mutational, methylation and transcriptomic features could allow identifying tailored therapies to improve CCA patient outcome. Proteomic remains partially unexplored; here, we analyzed the proteomic profile of five intrahepatic cholangiocarcinoma (ICC) derived from Italian patients undergone surgery and one normal bile duct cell line.
Proteome profile was investigated by using 2D electrophoresis followed by Mass Spectrometry (MS). To validate proteomic data, the expression of four overexpressed proteins (CAT, SOD, PRDX6, DBI/ACBP) was evaluated by immunohistochemistry in an independent cohort of formalin fixed, paraffin-embedded (FFPE) ICC tissues. We also compared proteomic data with those obtained by transcriptomic profile evaluated by microarray analysis of the same tissues.
We identified 19 differentially expressed protein spots, which were further characterized by MS; 13 of them were up- and 6 were down-regulated in ICC. These proteins are mainly involved in redox processes (CAT, SODM, PRDX2, PRDX6), in metabolism (ACBP, ACY1, UCRI, FTCD, HCMS2), and cell structure and organization (TUB2, ACTB). CAT is overexpressed in 86% of patients, PRDX6 in 73%, SODM in 100%, and DBI/ACBP in 81% compared to normal adjacent tissues. A concordance of 50% between proteomic and transcriptomic data was observed.
This study pointed out that the impairment of the metabolic and antioxidant systems, with a subsequent accumulation of free radicals, might be a key step in CCA development and progression.
胆管癌(CCA)是一种预后不良的侵袭性疾病。基于突变、甲基化和转录组特征的分子分类可以确定针对特定疗法,以改善 CCA 患者的预后。蛋白质组学仍部分未得到探索;在这里,我们分析了来自意大利手术患者的五个肝内胆管癌(ICC)和一个正常胆管细胞系的蛋白质组谱。
使用二维电泳(2D 电泳)后进行质谱分析(MS)来研究蛋白质组谱。为了验证蛋白质组学数据,通过免疫组织化学在独立的福尔马林固定、石蜡包埋(FFPE)ICC 组织队列中评估了四个过表达蛋白(CAT、SOD、PRDX6、DBI/ACBP)的表达。我们还将蛋白质组学数据与通过相同组织的微阵列分析评估的转录组谱数据进行了比较。
我们鉴定了 19 个差异表达的蛋白点,通过 MS 进一步进行了特征描述;其中 13 个上调,6 个下调。这些蛋白质主要涉及氧化还原过程(CAT、SODM、PRDX2、PRDX6)、代谢(ACBP、ACY1、UCRI、FTCD、HCMS2)以及细胞结构和组织(TUB2、ACTB)。与正常相邻组织相比,CAT 在 86%的患者中过表达,PRDX6 在 73%的患者中过表达,SODM 在 100%的患者中过表达,DBI/ACBP 在 81%的患者中过表达。蛋白质组学和转录组学数据之间观察到 50%的一致性。
这项研究指出,代谢和抗氧化系统的损伤,随后自由基的积累,可能是 CCA 发展和进展的关键步骤。